Tim Chiang
Stock Analyst at Capital One
(1.06)
# 3,754
Out of 5,182 analysts
20
Total ratings
33.33%
Success rate
-5.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Chiang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRTX Heron Therapeutics | Initiates: Overweight | $6 | $1.21 | +395.87% | 1 | Apr 23, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Overweight | n/a | $101.21 | - | 3 | Oct 30, 2023 | |
| JSPR Jasper Therapeutics | Initiates: Overweight | $70 | $0.93 | +7,429.31% | 1 | Aug 11, 2023 | |
| AMPH Amphastar Pharmaceuticals | Initiates: Overweight | $44 | $21.82 | +101.65% | 2 | Jul 29, 2022 | |
| KALA KALA BIO | Maintains: Outperform | $300 → $200 | $0.11 | +174,572.49% | 2 | Mar 30, 2022 | |
| PCRX Pacira BioSciences | Maintains: Market Perform | $75 → $66 | $25.41 | +159.74% | 3 | May 5, 2021 | |
| VRCA Verrica Pharmaceuticals | Initiates: Outperform | $210 | $6.53 | +3,115.93% | 1 | Jun 24, 2020 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Neutral | n/a | $31.62 | - | 6 | Sep 17, 2018 | |
| SMMT Summit Therapeutics | Initiates: Buy | $33 | $21.26 | +55.22% | 1 | Feb 13, 2018 |
Heron Therapeutics
Apr 23, 2024
Initiates: Overweight
Price Target: $6
Current: $1.21
Upside: +395.87%
Protagonist Therapeutics
Oct 30, 2023
Initiates: Overweight
Price Target: n/a
Current: $101.21
Upside: -
Jasper Therapeutics
Aug 11, 2023
Initiates: Overweight
Price Target: $70
Current: $0.93
Upside: +7,429.31%
Amphastar Pharmaceuticals
Jul 29, 2022
Initiates: Overweight
Price Target: $44
Current: $21.82
Upside: +101.65%
KALA BIO
Mar 30, 2022
Maintains: Outperform
Price Target: $300 → $200
Current: $0.11
Upside: +174,572.49%
Pacira BioSciences
May 5, 2021
Maintains: Market Perform
Price Target: $75 → $66
Current: $25.41
Upside: +159.74%
Verrica Pharmaceuticals
Jun 24, 2020
Initiates: Outperform
Price Target: $210
Current: $6.53
Upside: +3,115.93%
Teva Pharmaceutical Industries
Sep 17, 2018
Upgrades: Neutral
Price Target: n/a
Current: $31.62
Upside: -
Summit Therapeutics
Feb 13, 2018
Initiates: Buy
Price Target: $33
Current: $21.26
Upside: +55.22%